subscribe
 

Targeted skin cancer drug launches in UK

Vemurafenib, marketed by Roche as Zelboraf, is the first personalised treatment that has been shown in clinical trials to increase survival time for patients with a specific BRAF gene mutation. The European Commission has licensed the drug for adults with this mutation whose cancer is inoperable or which has spread.



Scientists find genetic key to why some cancer patients don't respond to treatment

Researchers from Newcastle University have identified a gene variation carried by 20 per cent of the population which can significantly affect how patients with a rare type of blood cancer will respond to treatment.



3D imagery to improve visualisation of liver cancer

Tumours can be highlighted so that surgeons can plan extraction operations more effectively



Smart cancer diagnostics

Test now enables respective mutations to be identified in routine laboratory operations



Vector network analysers for breast cancer screening research

Rohde and Schwarz has supplied high speed vector network analysers to Bristol University spin-out Micrima for the clinical trials



Switching drugs improves breast cancer patient survival rates

Trial examined the long-term effectiveness of switching to exemestane after two to three years of tamoxifen



UK-discovered prostate cancer drug launched in Britain

Treatment for prostate cancer works by blocking synthesis of testosterone in all tissues including the tumour itself



Liver transplant offers new option for rare cancer

Early results suggest significant improvements in survival for challenging bile duct cancer



Southampton researchers’ blood cancer breakthrough

Researchers at the University of Southampton have discovered clues to why many patients do not respond to a standard drug for the blood cancer lymphoma, raising hopes that more effective treatments can be designed



Tumour profiling assay to facilitate personalised cancer treatment

Oxford Gene Technology receives £1.16m award from the UK’s Technology Strategy Board



Focus on enhanced assays to detect cancer cells

Demand continues to grow for new and improved assays to detect cancer cells. The latest technologies, as Sean Ottewell reports, focus on rare cancer mutations, colorectal cancer recurrence and breast cancer.



Insights into cancer genome may lead to designer drugs for myeloma

Scientists used ‘next generation sequencing’ to map the cancer cell genomes of 38 patients with myeloma



Molecular target aims at aggressive prostate cancer

Researchers have identified a potential target to treat an aggressive type of prostate cancer



Study links vitamin D to lung cancer survival

Study finds an enzyme that plays a role in metabolizing vitamin D can predict lung cancer surviva



Gene test to predict nerve damage from bone cancer treatment

Scientists have found a genetic test that predicts whether bone marrow cancer treatments including thalidomide are likely to give patients a debilitating side-effect



Identifying microRNAs that can serve as biomarkers for prostate cancer

Researchers have identified serum microRNAs that can serve as biomarkers for prostate cancer



Patient trials of new leukaemia cancer vaccine

Treatment will use a new DNA vaccine which will treat a selected group of volunteers who have either chronic or acute myeloid leukaemia



New treatment strategy for bowel cancer patients

Scientists have found an important new drug target for advanced bowel cancer that could also be used to identify tumours that will respond to a drug already used in other cancers



New strategies for cancer drug development urgently needed

Millions of cancer patients may soon be able to receive more personalised treatments thanks to developments in the understanding of cancer biology



Finger length linked to prostate cancer risk

Men who have long index fingers are at lower risk of prostate cancer, a new study published today in the British Journal of Cancer has found



Pages

Subscribe

Subscribe



Newsbrief

Twitter Icon © Setform Limited
subscribe